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ABSTRACT  
The challenge faced by the majority of the pharmaceutical products is the poor solubility of the drug candidates which leads to low bioavailability. 
Liquisolid compact is one of the emerging techniques that enhances the dissolution of poorly water soluble drugs. Liquisolid system mentions to the 
formulation made by the transforming the liquid drug, either in the form of suspension or solution in non volatile solvents into a dry, non-sticky, 
free-flowing and compactable powder mixtures. This is achieved by mixing the suspension or solution of the drug with appropriate carriers and 
coating agents. The technology has the ability to increase aqueous solubility, rate of dissolution and absorption of poorly soluble drug by keeping it 
in molecularly dispersed form leading to its improved bioavailability when compared to conventional tablets. Liquisolid technology is the 
impending approach for enhancing the solubility of poorly water-soluble drug by adopting simple manufacturing process and low production cost.  
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Drugs belonging to biopharmaceutics classification system (BCS) 
class II encounter the problem of low solubility, dissolution rate 
which leads to poor bioavailability [1]. Micronization, lyophilization, 
solid dispersion, co-solvancy and complexing agents are the 
common methods employed to enhance the dissolution rate of BCS 
class II drugs. However, the liquisolid compacts are one of the 
successful procedures that improve the bioavailability of these drugs 
[2]. “Liquisolid technology” also referred to as “powder solution 
technology”. In this technology, a formulation is prepared by 
converting liquid drugs i. e solution or suspension from of drug in 
nonvolatile solvents into a dry non-sticky, compressible, smoothly 
flowing powder. This is achieved by mixing the drug suspension or 
solution with designated carriers and coating agents [3].  
The dissolution profile of the drugs was found to increase from 
liquisolid method due to the increased wetting properties and 
surface area. The technique is limited to low dose drugs with poor 
water solubility [4]. The carrier used in liquisolid compacts should 
have high adsorption properties and have a porous surface towards 
the liquid medication. The commonly used carrier in liquisolid 
compacts is microcrystalline cellulose (avicel PH 20, 102, 200) [5]. 
Coating material (E. g. silica) is used to cover the surface, to impart 
flowability to the powder and to provide content uniformity to the 
manufactured tablet dosage form. The rate of release of the drug, 
water solubility, and wettability can be increased by the use of 
disintegrants. (Eg; starch glycolate and crosspovidone). Nonvolatile 
solvents must be water miscible and should be able to impart 
binding action to the product (polyethene glycol 200,400 and 
glycerin) [6]. 
Advantages 
• The liquid-solid systems are versatile in the fact that it can be 
used for poorly soluble drugs.  
• Improves the bioavailability of water-insoluble drug candidates, 
which are given by oral route (E. g. Risperidone, Griseofulvin, 
Carvidelol).  
• When compared to soft gelatin capsules, the manufacturing 
expenditure is low. 
• The drug can be formulated as a tablet or a capsule or as an 
encapsulated liquisolid microsystem, where the drug is presented in 
solubilized state which leads to enhanced wetting phenomena and 
improvement in drug release profiles. 
• Instant release or continual release dosage forms can be 
formulated into liquisolid compact depending on the character of 
carriers used. 
• Drug release can be improved by using suitable formulation 
excipients such as hydrophobic carriers (Eudragit RL) for sustained 
release, use of surface active agents (polysorbate 80) for improved 
wettability and hence enhanced dissolution profile can be 
accomplished. 
• The technique can be scaled up to manufacturability. 
• When compared to conventional tablets the extent of absorption 
can be enhanced up to 15%. 
• The manufacturing efficiency can be improved [7-9]. 
Limitations 
• This methodology cannot be used to prepare high dose water-
insoluble drugs. 
• It is observed that there is an increase in weight of tablet due to 
presence of carrier material and coating materials in larger levels. 
• Application of mathematical calculations are required. 
• Faster drug release can be achieved by ingredients with high 
absorption capacity which provide smaller tablet size. 
• The inadequate hardness of liquisolid tablets results when 
acceptable compression is not achieved. 
• Dissolution rate and bioavailability depends on the solubility of 
drugs in non-volatile liquids [10-12]. 
Theoretical facts in the liquisolid system 
Only to a limited quantity of the liquid can be added above which the 
powder will lose its ability to retain the required flow and its 
compression properties.  
The mathematical approaches, as mentioned by Spireas include two 
decisive powder characteristics, Ф-value, which estimates the 
maximum liquid retention potential of powder with acceptable flow 
behavior. By measuring the rate of flow or repose angle, the 
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flowability can be calculated. The Ψ-number this parameter gives an 
indication about compressible nature of powder with an adequate 
hardness along with maximum liquid retention potential. The 
compatibility determies the maximum crushing strength of unit 
weight of tablets. 
Another important parameter is excipients ratio (ER), which 
represents the weight of carrier (C) to the coating agent (CA) 
present in the formulation:  
CA
CER =
 …….. (1) 
The ER values of the powder substrate depends maximum liquid on 
carrier. An excipient ratio which can result in a liquid system with 
adequate flowability and compressibility, only the conditions where 
the liquid load on the carrier material is not over exceeded. This 
ratio is designated as “liquid load factor” LLf [w/w] is the weight of 
the liquid formulation (W) to the carrier material (C) in the system:  
C
WLLf =  ………. (2) 
The (LLf) guarantees adequate flow behavior (ΦLLf) and is 
determined by:  
( )ERLLf 1.ψφ +Φ=  …….. (3) 
In the same way, the liquid load factor for liquisolid systems with 
satisfactory compatibility (ΨLf) can be determined by:  
( )ERLLf 1.Ψ+Ψ=Ψ  …….. (4) 
Therefore, the optimum liquid load factor (LLo) necessary for 
obtaining most favourable flow behavior and compressibility of the 
system is either ΦLLf or ΨLLf, whichever is lesser in magnitude. 
Once the optimum LLF is calculated, accurate amounts of the carrier 
(C) and coating agent (CA) necessary for conversion of the particular 
quantity of liquid formulation (W) into an almost flowing and 







 ……… (6) 
Mechanism involved in improved drug release profile from 
liquisolid systems 
Various literature reports emphasis that, the liquisolid system has 
been used to improve release rate of weakly soluble and low dose 
drugs. The incorporation of high dose water-insoluble drugs can be 
achieved by additives polyvinyl pyrrolidine (PVP), hydroxyl propyl 
methyl cellulose (HPMC), polyethene glycol (PEG) 35000 [15]. These 
additives can increase the liquid absorption capacity of carrier and 
coating material [16]. The responsible mechanism for enhanced 
drug release is given below:  
Augmented surface area 
The increase in the surface area of the drug in a liquisolid system 
(fig. 1) results from a complete dissolution of the drug in a liquid 
vehicle which represents the drug insolubilized and molecularly 
dispersed state [16].  
 
 
Fig. 1: Increased drug surface area [19] 
 
A comparison between directly compressed tablets and tablets 
prepared liquisolid technique suggested that the drug release from 
latter was at a higher rate. The molecularly dispersed fraction of drug 
in liquid formulation is given by solubility of the drug divided by drug 
concentration which is expressed by the following equations [17]: 
C
SFm =
 …….. (7) 
Where, 
CSFm ≥=1  …….. (8) 
Fig. 2 represents the relation between molecularly dispersed states 
of the hydrocortisone from liquisolid compacts when propylene 
glycol (PG) was used as liquid media. 
Improved aqueous solubility of the drug 
Enhancement in the water solubility of the drug is due to the presence 
of a solid-liquid boundary between liquisolid primary particles and the 
media surrounding it. The quantity of the vehicle diffuses along with 
drug particle from the micro environmental condition contributes for 
an increase in the aqueous solubility (fig. 3), may be due to the co-
solvent effect of the vehicle [20]. 
Improved wetting properties  
The liquid vehicle has surface active properties which reduce the 
surface tension, results in the wetting of primary particles. The 
wettability can be determined by contact angle measurements (fig. 4) 
and the water rising time [21]. 
 
 
Fig. 2: Effect on the release rate of hydrocortisone liquisolid compacts 
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Fig. 3: Increased aqueous solubility of the drug [19] 
 
 
Fig. 4: Depiction of the contact angle of the conventional and liquisolid tablet [18] 
 
Porosity 
Pezzini et al. reported that liquisolid technology leads to soft 
structures with a high porosity which enhances the disintegration and 
dissolution process of liquisolid compacts of felodipine pellets [22]. 
Mechanism of sustained drug release from liquisolid systems 
The replacement of the usual hydrophilic carrier with the 
hydrophobic carrier can lead to poor wetting which results in slow 
disintegration and thus extends the release of the drug. It is 
observed that there is neither a change in crystalline nature of drug 
nor a complex formation takes place during the process of liquid-
solid compacts. This observation is much confirmed by X-ray 
crystallography and DSC measurements [23]. Another reason for 
decreased drug release is the influence of liquid vehicle, which was 
evident from the comparative study of directly compressed matrix 
tablets prepared of Eudragit® RS or RL as matrix forming material 
and liquisolid compacts, contains polysorbate 80 as liquid vehicle. 
Further, retardation was observed to a higher extent for the release 
of the drug from the liquisolid compact in contrast to conventional 
matrix tablets [24]. The coalescence observed with polymer 
particles in liquisolid compacts is much lower than with traditional 
matrix tablets. The reason for decreased drug release is due to the 
distinct coalescence of polymer particles, leads to decreased 
porosity and increased tortuosity [25]. The hydrophobicity of the 
polymer may contribute to the sustained release of the drug. The use 
of HPMC in the hydrophilic matrix system retards the drug-retaining 
by undergoing molecular weight dependent swelling. This system, 
when contact with water either swells or erodes results in zero 
order kinetics [27]. It is reported that the drug retardation effect 
from HPMC liquisolid compacts was more evident in comparison to 
directly compressed tablets [28].  
Formulation of liquisolid compacts  
Liquisolid compacts formula contains a carrier, coating material, 
nonvolatile solvent, disintegrants, lubricants and binding agents 
(table 1). 
Carrier material 
The carrier used should be spongy in nature, should posses satisfactory 
absorption properties for a liquid vehicle, both carrier as well as coating 
materials should hold a limited quantity of liquid, at the same time it 
should maintain flowability and compressibility. E. g, microcrystalline 
cellulose (MCC) (avicel PH 200 and avicel PH 102) [33]. 
Coating material 
Coating materials are usually coarsely powdered particles which 
provide covering to the particles that are wet by adsorbing the 
excess of liquid, results in a dry free-flowing powder. E. g:-Various 
grades of silica (Syloid 244FP, Cab-O-Sil M5 and Aerosil 200) [34]. 
Nonvolatile solvent 
Solvents used are nonvolatile, water-miscible, inert and not extremely 
viscous. They should have a high boiling point, possess good 
solubilization power for drugs used. Binding action can also be provided 
within the formulation with the help of nonvolatile liquids. E. g:-glycerin, 
polysorbate 80, propylene glycol, polyethylene glycol 200 and 400 [35]. 
Disintegrating agents (disintegrants) 
These are agents which take up water, increases wettability, water 
solubility and the rate of drug release. The breakup of compacts into 
smaller particles can be achieved by the use of disintegrants. E. g 
sodium starch glycolate and cross-povidone, explotab and 
pregelatinized starch [36]. 
Drug candidate 
BCS class II and IV drugs are generally choosen as a drug candidate 
for the liquisolid system. This results in increased water solubility of 
such candidates. E. g.-Naproxen, Digitoxin, Prednisolone, 
Hydrocortisone, Ketoprofen [37]. 
Methodology 
The required quantities of the drug and stated quantity of 
nonvolatile solvent is weighed, mixed and heated (if required) 
results in a solution of the drug. Carrier and coating materials is 
incorporated into the drug solution. The process of mixing is to be 
done as three stages as recommended by Spireas et al. (fig. 5) [39]. 
First stage 
The weighed ingredients are to be combined at an estimated mixing 
rate of one rotation/second/minute, which will aid the liquid 
medication to contribute its role in the powder [40]. 
Second stage 
The above mixture should be spread evenly on a mortar surface for 
about 5 min. This results in complete absorption of drug solution 
into the voids of powder particles [41]. 
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Third stage 
The above blend is to be mixed with a super disintegrant for 30 sec 
at a blending speed, which will results in the final blend ready for 
compression [42]. 
Preformulation studies 
Preformulation studies performed to confirm the physiochemical 
characterization and it includes the following studies [44]. 
• Solubility studies of the drug in solvents 
• Sliding angle determination 
• Flowable liquid retention potential 
• liquid load factor (LLf) 
• Liquid-solid compressibility test (LSC)  
The solubility of drug in non-volatile solvents 
A saturated solution of the drug is prepared and is used for solubility 
studies. A surplus of the drug is added to vehicles which results in 
saturated solution by employing the shaker for the solution at a 
given period of time under steady vibration. The filtrate of the drug 
solutions are then analyzed spectrophotometrically. 
 
Table 1: Components and physical characteristics of the Liquisolid technique 
Components Drug candidates Nonvolatile solvent Carrier materials Coating materials Reference  
Properties Low dose with BCS class II 
and IV 
Water-miscible ability to solubilise 















Fig. 5: Schematic representation of liquisolid preparation [43] 
 
Angle of slide 
Sliding angle measures the flow behavior of powders. A metallic 
plate with a smooth surface is used for the test, where the test 
powder is placed at one end of it, is gradually raised till the plate 
becomes angular to the horizontal plane, at which the powder just 
slides. The powder having an angle of 33° provides optimum flow 
characteristics.  
Liquid flowable liquid retention potential (Φ) 
It shows liquid retention potential of the powder with adequate flow 
behavior. 
Liquid load factor (LLf) 
It is the ratio of the weight of liquid medication (W) to the weight of 
carrier material (C). This is determined by taking adequate 
quantities of nonvolatile solvents in which the drug is dissolved, 
resulting solution is converted to a free flowing powder by addition 
of carrier and coating materials.  
Liquisolid compressibility test (LSC) 
This test determines the Ψ values (compressible liquid retention 
value). It is done by preparation of carrier and coating material 
admixture, converting the admixtures into tablets. The average rigidity 
is measured by the average liquid content of crushed tablets [45, 46].  
Evaluation of liquisolid system 
• Flow behaviour  
• Differential Scanning Calorimetry (DSC) 
• X-ray diffraction (XRD) 
• Scanning Electron Microscopy (SEM) 
• Dissolution testing 
• In vivo evaluation  
Flow behavior 
Bulk density 
Weighed quantities of the powder blend is transferred into a 
graduated measuring cylinder. The bulk volume (Vb) of the 
weighted amount of the powder (W) is determined. Bulk density is 
given below:  
Vb
WdensityBulk =
 ……… (8) 
Tapped density 
The weighed amount of powder mass is poured to a graduated 
measuring cylinder and tapped for a fixed number of times and the 
volume is determined (Vt). Tapped density can be given by, 
Vt
WdensityTapped =
 …… (9) 
Compressibility index 
Compressibility index is given by the following equation:  
100)/( ∗−= itytappeddensybulkdensitdensitytappedindexilityCompressib
 ……….. (10) 
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Compressibility index values lower than 15 % shows good flow 
characteristics of powders and values higher than 25 % indicate 
poor flow nature. 
Hausner’s ratio 
The indirect measurement of flow pattern of powders is given by:  
densityBulk
densityTappedratiosHausner =,
 ……… (11) 
A value below<1.25 indicates good flow behavior, whereas>1.5 
signify poor flowability. Hausner’s ratio can vary depending on 
method used for the determination, so it is not taken as a critical 
parameter in flow behaviour. Flow property of powders are 
represented in the table 2 
Angle of repose 
The powder blend is passed through a funnel that is made to ascend 
vertically till the funnel tip touches the pile of the powder. The 
height of pile (h) and radius of the base of powder pile (r) is 





Table 2: Flow behaviour of the powder 
Compressibility index Haussner’s ratio Flowability Reference  
5-15% 1.05-1.18 Excellent 47 
 12-16% 1.14-1.19 Good 
18-21% 1.22-1.27 Fair-passable 
23-35% 1.30-1.54 Poor 
33-38% 1.49-1.69 Very poor 
>40% >1.67 Very very poor 
 
Differential scanning calorimetry (DSC) 
Thermal behavior of the pure components and the liquisolid 
compacts can be assessed by DSC studies. About 3–5 mg of the 
sample is vacuum-packed in aluminium pans exposed to the 
invariable rate of heating 10 °C/min at a temperature range of 30 to 
300 °C. Aluminum pans which are vacant are used as references and 
by purging nitrogen, the entire thermal behavior is studied. The 
absence of characteristic peak of the drug in presence of excipients 
is an indication of incompatibility of drug with excipients as well as 
changes in the crystalline pattern of the drug, may be a molecular 
level changes from a crystalline to amorphous pattern [49]. 
X-ray diffraction (XRD) studies 
XRD studies determines the crystalline property of the liquisolid 
compact mixture by X-Ray diffractometer. The study uses a current 
of 30 mA and copper target at a voltage of 40 kV. The instrument 
works at a scanning angle of 5 to 70 ° and a counting rate of 0.4 
s/step. The change in the peak pattern from distinct and sharp to 
random pattern gives an evidence about the conversion of 
crystalline nature of drugs to amorphous forms of drug [50]. 
Scanning electron microscopy 
This technique helps in determining the surface behavior of the 
drug, which gives an idea whether the drug is crystallized from the 
liquisolid system. The solubilized nature of the drug in liquisolid 
system results in the disappearance of these molecular forms [51]. 
In vitro drug release studies 
In vitro release studies of the liquisolid tablets is performed using 
USP dissolution apparatus type II. The studies are carried out in 900 
ml 0.1 N HCl maintained at a constant temperature 37 °C±2 °C at a 
stirring speed of 50 to 200 rpm. After adding a known amount of 
drug equal formulation into the media, the percentage of drug 
dissolved is determined by withdrawing the samples at regular 
intervals and sink conditions are maintained by replacing with fresh 
buffer. The drug concentration can be determined spectro-
photometrically (table 3) [51, 52].  
 
Table 3: Conditions required for in vitro drug release studies 
In vitro release parameters Criteria  Reference 
Medium Phosphate buffer pH 7.4 51 
 Apparatus Basket type USP 24 (type II) 
Medium volume 900 ml 
 Speed 200 rpm 
Temperature 37.0±0.5 °c 
Wave length 282 nm 
 
In vivo evaluation of liquisolid tablets 
The comparative plasma concentration profile of the drug from the 
liquisolid compact in comparison to a commercial tablet should 
show a significant difference in area under plasma concentration 
profile, relative bioavailability, and peak plasma concentration [53]. 
Applications  
Dissolution of drugs can be improved by liquisolid technique: 
Dissolution rate of low dose insoluble drugs such as Prednisolone 
[40], Famotidine [54], Valsartan [55] etc (table 4) can be enhanced 
by the use of the liquisolid technique. 
 
Table 4: Liquisolid formula with improved drug release 
Drug Liquid vehicle Carrier and coating material Reference  
Aceclofenac PEG 400 MCC and HPMC [21] 
 Famotidine PG MCC and Aerosil  
Ibuprofen PEG 300 MCC and Aerosil 
Prednisone PG MCC and Aerosil 
Piroxicam Polysorbate 80 MCC and Aerosil 
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Incorporation of high dose water-insoluble drugs: by employing few 
additives such as PVP, HPMC and polyethylene glycol 35000, large 
dose, poorly soluble could be incorporated into liquisolid systems. 
This may be due to the fact that, these additives have the 
capability to increase the liquid uptake nature of carrier and 
coating materials and also by using modern carriers (such as 
Neusilin®) with augmented effective surface and greater 
absorption capacity [56]. 
Sustain drug release: Liquisolid technique a promising method for 
preparing the persistent release formulations of different drugs, as 
reported in the table 5 [57]. 
 
Table 5: Formulation of the liquisolid system with sustained drug release 
Drug Liquid vehicle Carrier and coating material Additional retardant agent Reference  
Nifedipine PEG 400 MCC and colloidal silica HPMC [29] 
Propranolol Polysorbate 80 Eudragit and colloidal silica HPMC [30] 
Theophylline Polysorbate 80 Eudragit and colloidal silica HPMC [31] 
Tramadol PG MCC and colloidal silica HPMC [32] 
 
The control of pH deviation on drug release can be reduced by using 
liquisolid technology. When compared to marketed tablets and 
directly compressed tablets, the dissolution rate of liquisolid tablets 
is more and less affected by pH deviation on drug release [56]. 
Drug photostability in solid dosage forms can be enhanced by this 
method [56]. 
Liquisolid technology can be applied in probiotics [57]. 
CONCLUSION 
Liquisolid technology is the impending move towards enhancing the 
solubility of the water-insoluble drug by using a simple 
industrialized process and lower production cost by the use of 
relatively inexpensive excipients. Due to the enhanced water 
solubility and dissolution rate, the extent of absorption of drugs can 
be increased. It can also be employed to design immediate and 
sustained release system by means of hydrophilic and hydrophobic 
carriers. Liquisolid technology employs liquid portion as 
suspensions or solution of poorly soluble drugs in a suitable 
nonvolatile liquid vehicle which are then changed to effortlessly 
smooth and compactable powders by simple physical blending with 
particular ingredients such as carrier and coating agent. This 
technology is found to be truly promising as the solubility and 
dissolution related problems of drugs, especially BCS class II and IV 
which leads to poor bioavailability can be surmounted as reported in 
the literatures.  
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